A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

Learn more about:
Related Clinical Trial
The Effects of Baduanjin Qigong Exercise on Ankylosing Spondylitis: A Randomized Controlled Study Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan Assessment of Predictive Factors for Persistence of Treatment After Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases the Relationship Between Abnormal Modified Schober Index and Demographic Characteristics and Clinical Variables Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Hematological Parameters in Axial Spondyloarthritis Yuflyma® (Adalimumab), Patient Experience After Switching Ozone Therapy in Ankylosing Spondylitis Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis. A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis The Effects of Jing Si Herbal Tea Liquid Packets on Fatigue in Patients With Inflammatory Arthritis Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS bIosimilar of aDalimumab, an European evAluation Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Brief Title

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

Official Title

A Multicenter Study Evaluating the Efficacy and Safety of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis.

Brief Summary

      The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in
      Chinese adults participants with active ankylosing spondylitis (AS) who have had an
      inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or
      intolerance to or a contraindication for NSAIDs, and who are naïve to biologic
      disease-modifying anti-rheumatic drugs (bDMARD).

Detailed Description

      This study includes two periods: a 16-week double-blind placebo-controlled period and a
      52-week open-label long-term extension period.

      Eligible participants were randomly assigned in a 1:1 ratio to receive secukinumab 300 mg or
      placebo for 16 weeks in Period 1.

      Participants who completed Period 1 received secukinumab 300 mg for 36 weeks in the extension

Study Phase

Phase 4

Study Type


Primary Outcome

Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 24

Secondary Outcome

 Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 48


Ankylosing Spondylitis (AS)


Secukinumab 300mg s.c.

Study Arms / Comparison Groups

 Secukinumab 300mg
Description:  Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 300 mg s.c. every 4 weeks for an additional 48 weeks.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

June 14, 2021

Completion Date

August 31, 2022

Primary Completion Date

August 31, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the
             modified New York criteria for AS.

          -  Participant must have baseline disease activity as defined by having a Bath Ankylosing
             Spondylitis Disease Activity Index (BASDAI) score >= 4 and a Patient's Assessment of
             ●Total Back Pain score >= 4 based on a 0 - 10 numeric rating scale (NRS) at the
             Screening and Baseline visits.

          -  Participant has had an inadequate response to at least two nonsteroidal
             anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum
             recommended or tolerated doses, or participant has an intolerance to or
             contraindication for NSAIDs as defined by the Investigator.

          -  If entering the study on concomitant methotrexate (MTX), leflunomide, sulfasalazine
             (SSZ), and/or hydroxychloroquine, participant must be on a stable dose of MTX (<= 25
             mg/week) and/or SSZ (<= 3 g/day) and/or hydroxychloroquine (<= 400 mg/day) or
             leflunomide (<= 20 mg/day) for at least 28 days prior to the Baseline visit. A
             combination of up to two background conventional synthetic disease-modifying
             anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and

          -  If entering the study on concomitant oral corticosteroids, participant must be on a
             stable dose of prednisone (<= 10 mg/day), or oral corticosteroid equivalents, for at
             least 14 days prior to the Baseline visit.

          -  If entering the study on concomitant NSAIDs, tramadol, combination of acetaminophen
             and codeine or hydrocodone, and/or non-opioid analgesics, participant must be on
             stable dose(s) for at least 14 days prior to the Baseline visit.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Prior exposure to any biologic therapy with a potential therapeutic impact on
             spondyloarthritis (SpA).

          -  Intra-articular joint injections, spinal/paraspinal injection(s), or parenteral
             administration of corticosteroids within 28 days prior to the Baseline visit. Inhaled
             or topical corticosteroids are allowed.

          -  Participant on any other DMARDs (other than those allowed), thalidomide or apremilast
             within 28 days or five half-lives (whichever is longer) of the drug prior to the
             Baseline visit.

          -  Participant on opioid analgesics (except for combination acetaminophen/codeine or
             acetaminophen/hydrocodone which are allowed) or use of inhaled marijuana within 14
             days prior to the Baseline visit.

          -  Participant has a history of inflammatory arthritis of different etiology other than
             axial SpA (including but not limited to rheumatoid arthritis, psoriatic arthritis,
             mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis,
             scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset
             prior to 17 years of age.

          -  Laboratory values meeting the following criteria within the Screening period prior to
             the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal
             (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by
             simplified 4-variable Modification of Diet in Renal Disease formula < 40 milliliter
             (mL)/minute/1.73m^2; hemoglobin < 10 gram/deciliter, total white blood cell count <
             2,500/microliter (μL); absolute neutrophil count < 1,500/μL; absolute lymphocyte count
             < 800/μL; and platelet count < 100,000/μL.




18 Years - 80 Years

Accepts Healthy Volunteers



AIHUA DU, M.D, 15671678920, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Tongji Hospital


 Wuhan Central Hospital

Study Sponsor

AIHUA DU, M.D, Study Chair, Tongji Hospital

Verification Date

March 2022